An interventional study of Continuous Positive Airway Pressure (CPAP) in PCOS, PCOS (Polycystic Ovary Syndrome) and OSA, sponsored by University of Chicago. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by University of Chicago · Not applicable, Interventional, and Other
The goal of this study is to obtain pilot data investigating the effects of sleep apnea on mitochondrial function and cellular metabolism in Polyendocrine Metabolic Ovarian Syndrome (PMOS) patients.
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, with symptoms commonly manifesting in reproductive abnormalities. PCOS was recently reclassified as Polyendocrine Metabolic Ovarian Syndrome (PMOS) to better describe the multi-systemic and endocrine nature of the disorder. Beyond reproductive concerns, PMOS patients are at significantly higher risk of developing diabetes. Similarly, PMOS patients are at a higher risk of presenting with Obstructive Sleep Apnea (OSA). While it is known that OSA contributes to metabolic dysfunction, this effect has been shown to be disproportionately larger in individuals with pre-existing metabolic dysfunction.With the wider recognition of PMOS as a metabolic disorder, and despite the known link between PMOS and OSA, there are no studies investigating the effects of OSA in a PMOS population. Metabolic dysfunction in skeletal muscle is part of the PMOS phenotype. The research team will use high resolution respirometry on skeletal muscle biopsies- a cutting-edge method for assessing changes in mitochondrial function and cellular metabolism. Muscle biopsies will be done with and without OSA treatment (Continuous Positive Air Pressure- CPAP) as an investigation into the effect of OSA on mitochondrial function.
975 studies on the registry are indexed under Polycystic Ovary Syndrome; 177 are open to participants now.
This study's planned enrollment of 10 is below the median of 70 across 710 interventional studies indexed under Polycystic Ovary Syndrome.
Browse Polycystic Ovary Syndrome studies →University of Chicago is the lead sponsor of 924 studies on the registry; 186 are open to participants now.
Of its 102 completed or terminated interventional studies of FDA-regulated products, 71 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Treated with Continuous Positive Airway Pressure (CPAP).
Device: Continuous Positive Airway Pressure (CPAP)
Two nights of CPAP treatment for OSA.
Complex I and II/Electron Transport System Capacity
A measure of mitochondrial function that takes a ratio of the phenotypic maximal respiration of mitochondria isolated in muscle fibers taken via biopsy relative to the maximal non-physiological respiratory capacity as determined via the maximal rate of oxygen consumption induced by a chemical uncoupler.
Time frame: Muscle biopsy will be collected during the treated condition and untreated condition. Mitochondrial function will be compared from both. These take place in a random order, 2-4 weeks apart.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.